Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
Change from baseline in the quantified gait analysis kinematic, dynamic and mechanical work parameters
Walking and mobility
Other measures (1)
-comparison of change after treatment, of quantified parameters of electromyography and energy cost an gait analysis
Walking and mobility
Who could take part
MS (type not specified)
Inclusion: To be eligible to participate in this study, candidates must meet the following eligibility criteria: Exclusion: Candidates will be excluded from study entry if any of the following exclusion criteria are met at the screening visit or at any time during the screening period:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of the study is to assess the effect of treatment with prolonged-release fampridine 10 mg twice, on the quantified gait analysis parameters (kinematics, dynamics, mechanical work).
Loading reviews and guidelines…
Related trials
- AmpPT
Phase 3 · Recruiting
Still running
- RESTORE
Phase 3 · Stopped early
Stopped: not working
- New strategies in neurological diseases
Phase 4 · Ongoing
Still running
- MUST
Not a drug-phase study · Completed
Result in a paper, not read yet
- FAMILY
Completed
Result in a paper, not read yet
- Fampridine Study in Activities of Daily Living
Phase 4 · Completed
No result found
History
Started
Dec 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error